Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A. Beckett, Nigel J. Cairns, Jesse Cedarbaum, Michael C. Donohue, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, John C. Morris, Ronald C. Petersen, Andrew Saykin, Leslie Shaw, Paul M. Thompson, Arthur W. Toga, John Q. Trojanowski

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

Original languageEnglish
Pages (from-to)865-884
Number of pages20
JournalAlzheimer's and Dementia
Volume11
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Neuroimaging
Alzheimer Disease
Biomarkers
Clinical Trials
Publications
Public-Private Sector Partnerships
Outcome Assessment (Health Care)
Information Dissemination
Post-Traumatic Stress Disorders
Patient Selection
Multiple Sclerosis
Parkinson Disease
Disease Progression
Alleles
Depression
Ligands

Keywords

  • AD biomarker signature
  • Alzheimer's disease
  • Amyloid phenotyping
  • Clinical trial biomarkers
  • Data-sharing
  • Tau imaging
  • Worldwide ADNI

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Cite this

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., ... Trojanowski, J. Q. (2015). Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 11(7), 865-884. https://doi.org/10.1016/j.jalz.2015.04.005

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. / Weiner, Michael W.; Veitch, Dallas P.; Aisen, Paul S.; Beckett, Laurel A.; Cairns, Nigel J.; Cedarbaum, Jesse; Donohue, Michael C.; Green, Robert C.; Harvey, Danielle; Jack, Clifford R.; Jagust, William; Morris, John C.; Petersen, Ronald C.; Saykin, Andrew; Shaw, Leslie; Thompson, Paul M.; Toga, Arthur W.; Trojanowski, John Q.

In: Alzheimer's and Dementia, Vol. 11, No. 7, 01.07.2015, p. 865-884.

Research output: Contribution to journalArticle

Weiner, MW, Veitch, DP, Aisen, PS, Beckett, LA, Cairns, NJ, Cedarbaum, J, Donohue, MC, Green, RC, Harvey, D, Jack, CR, Jagust, W, Morris, JC, Petersen, RC, Saykin, A, Shaw, L, Thompson, PM, Toga, AW & Trojanowski, JQ 2015, 'Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014', Alzheimer's and Dementia, vol. 11, no. 7, pp. 865-884. https://doi.org/10.1016/j.jalz.2015.04.005
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia. 2015 Jul 1;11(7):865-884. https://doi.org/10.1016/j.jalz.2015.04.005
Weiner, Michael W. ; Veitch, Dallas P. ; Aisen, Paul S. ; Beckett, Laurel A. ; Cairns, Nigel J. ; Cedarbaum, Jesse ; Donohue, Michael C. ; Green, Robert C. ; Harvey, Danielle ; Jack, Clifford R. ; Jagust, William ; Morris, John C. ; Petersen, Ronald C. ; Saykin, Andrew ; Shaw, Leslie ; Thompson, Paul M. ; Toga, Arthur W. ; Trojanowski, John Q. / Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. In: Alzheimer's and Dementia. 2015 ; Vol. 11, No. 7. pp. 865-884.
@article{542d874cc3ef4a9696037d010790cc21,
title = "Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014",
abstract = "Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.",
keywords = "AD biomarker signature, Alzheimer's disease, Amyloid phenotyping, Clinical trial biomarkers, Data-sharing, Tau imaging, Worldwide ADNI",
author = "Weiner, {Michael W.} and Veitch, {Dallas P.} and Aisen, {Paul S.} and Beckett, {Laurel A.} and Cairns, {Nigel J.} and Jesse Cedarbaum and Donohue, {Michael C.} and Green, {Robert C.} and Danielle Harvey and Jack, {Clifford R.} and William Jagust and Morris, {John C.} and Petersen, {Ronald C.} and Andrew Saykin and Leslie Shaw and Thompson, {Paul M.} and Toga, {Arthur W.} and Trojanowski, {John Q.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.jalz.2015.04.005",
language = "English",
volume = "11",
pages = "865--884",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

AU - Weiner, Michael W.

AU - Veitch, Dallas P.

AU - Aisen, Paul S.

AU - Beckett, Laurel A.

AU - Cairns, Nigel J.

AU - Cedarbaum, Jesse

AU - Donohue, Michael C.

AU - Green, Robert C.

AU - Harvey, Danielle

AU - Jack, Clifford R.

AU - Jagust, William

AU - Morris, John C.

AU - Petersen, Ronald C.

AU - Saykin, Andrew

AU - Shaw, Leslie

AU - Thompson, Paul M.

AU - Toga, Arthur W.

AU - Trojanowski, John Q.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

AB - Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

KW - AD biomarker signature

KW - Alzheimer's disease

KW - Amyloid phenotyping

KW - Clinical trial biomarkers

KW - Data-sharing

KW - Tau imaging

KW - Worldwide ADNI

UR - http://www.scopus.com/inward/record.url?scp=84937573808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937573808&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2015.04.005

DO - 10.1016/j.jalz.2015.04.005

M3 - Article

C2 - 26194320

AN - SCOPUS:84937573808

VL - 11

SP - 865

EP - 884

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 7

ER -